within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC02_Salbutamol;

model Salbutamol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 7.316666666666666e-06,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Salbutamol</td></tr><tr><td>ATC code:</td><td>R03AC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>439</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Salbutamol (also known as albuterol) is a short-acting beta-2 adrenergic agonist used primarily for the relief and prevention of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is commonly administered via inhalation but can also be given orally or intravenously in specific clinical situations. It is an approved medication and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Marques, L, &amp; Vale, N (2024). Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients. <i>Pharmaceutics</i> 17(1) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics17010039\">10.3390/pharmaceutics17010039</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39861686/\">https://pubmed.ncbi.nlm.nih.gov/39861686</a></p></li><li><p>Tan, WC, &amp; Lee, HS (1991). Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. <i>European journal of clinical pharmacology</i> 41(5) 495–496. DOI:<a href=\"https://doi.org/10.1007/BF00626378\">10.1007/BF00626378</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1761082/\">https://pubmed.ncbi.nlm.nih.gov/1761082</a></p></li><li><p>Heuberger, JAAC, et al., &amp; Cohen, AF (2018). Futility of current urine salbutamol doping control. <i>British journal of clinical pharmacology</i> 84(8) 1830–1838. DOI:<a href=\"https://doi.org/10.1111/bcp.13619\">10.1111/bcp.13619</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29722428/\">https://pubmed.ncbi.nlm.nih.gov/29722428</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Salbutamol;
